In a recent publication in Nature Immunology, Bruchard et al. report that type 3 innate lymphoid cells, activated and recruited by cisplatin-induced chemokine ligand 20 (CCL20) and interleukin-1 beta (IL-1b), promote CD4 and CD8 T cell infiltration into murine tumors. This turns "cold'' tumors "hot'', thereby enhancing responsiveness to immune checkpoint inhibitors.
展开▼
